Syncona Portfolio Ltd

In its 13F for Q1 2024 (holdings as of March 31, 2024, filed May 7, 2024), Syncona Portfolio Ltd reported 2 stock positions worth $150.1 million. Its top holding was Autolus Therapeutics (AUTL) at 90.8% of the portfolio, followed by Achilles Therapeutics PL-ADR (ACHL, 9.2%). Compared with Q4 2023, it sold out of 2. The biggest sale was an exit from Freeline Therapeutics (FRLN).

Most Recent 13F
Q2 2026
Location
St Peter Port, Guernsey, X0
CIK
0001725042
Portfolio Value
$150.1M (Q1 2024)
SEC Filing
0000950123-24-003925 ↗ filed May 7, 2024

Holdings Value

0$50.0M$100.0M$150.0M$200.0M Q1 2024: $150.1M $150.1M Q1 2024 Q2 2024: $85.9M Q2 2024 Q3 2024: $80.7M Q3 2024 Q4 2024: $53.0M Q4 2024 Q1 2025: $26.4M Q1 2025 Q2 2025: $38.6M Q2 2025 Q3 2025: $27.7M Q3 2025 Q4 2025: $34.3M Q4 2025 Q1 2026: $25.7M Q1 2026 Q2 2026: $26.6M Q2 2026

Holdings 2 stocks · $150.1M
AUTL Autolus Therapeutics PLC 90.76% 21,346,829 $136.2M No change
ACHL Achilles Therapeutics PL-ADR 9.24% 11,086,909 $13.9M No change

Portfolio Sells Q4 2023 → Q1 2024
FRLN Freeline Therapeutics Hldgs Sold out 0.00% −5.91
ADAPY Adaptimmune Therapeutics-ADR Sold out 0.00% −0.69

Portfolio Buys Q4 2023 → Q1 2024
None this quarter.

All Filings

QuarterPositions13F Reported ValueTop Holdings
Q2 2026 1$26.6MAUTL
Q1 2026 2$25.7MAUTL, IPSC
Q4 2025 2$34.3MAUTL, IPSC
Q3 2025 2$27.7MAUTL, IPSC
Q2 2025 2$38.6MAUTL, IPSC
Q1 2025 2$26.4MAUTL, IPSC
Q4 2024 3$53.0MAUTL, ACHL, IPSC
Q3 2024 3$80.7MAUTL, ACHL, IPSC
Q2 2024 3$85.9MAUTL, ACHL, IPSC
Q1 2024 2$150.1MAUTL, ACHL